These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36700734)

  • 1. Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.
    Desch M; Schlecker C; Hohl K; Liesenfeld KH; Chan T; Müller F; Wunderlich G; Keller S; Ishiguro N; Wind S
    J Clin Psychopharmacol; 2023 Mar-Apr 01; 43(2):113-121. PubMed ID: 36700734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.
    Ou YC; Tang Z; Novotny W; Tawashi M; Li TK; Coleman HA; Sahasranaman S
    Br J Clin Pharmacol; 2021 Jul; 87(7):2926-2936. PubMed ID: 33336408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
    Kim MG; Kim Y; Jeon JY; Kim DS
    Br J Clin Pharmacol; 2016 Dec; 82(6):1580-1590. PubMed ID: 27495955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein.
    Zahir H; Kobayashi F; Zamora C; Gajee R; Gordon MS; Babiker HM; Wang Q; Greenberg J; Wagner AJ
    J Clin Pharmacol; 2021 Mar; 61(3):298-306. PubMed ID: 32918831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
    Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
    Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.
    Fu M; Luo L; Feng S; Lin H; Lu Z; Gu F; Fan Y; Wu B; Huang J; Shen K
    Br J Clin Pharmacol; 2023 Dec; 89(12):3659-3668. PubMed ID: 37464978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
    Tachibana M; Papadopoulos KP; Strickler JH; Puzanov I; Gajee R; Wang Y; Zahir H
    Br J Clin Pharmacol; 2018 Jan; 84(1):112-121. PubMed ID: 28865153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects.
    Greene SA; Kwak C; Kamin M; Vernillet L; Glenn KJ; Gabriel L; Kim HW
    Clin Transl Sci; 2022 Apr; 15(4):899-911. PubMed ID: 34877801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
    Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
    Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects.
    Berger B; Kaufmann P; Berse M; Treiber A; Grignaschi N; Dingemanse J
    Pharmacol Res Perspect; 2023 Oct; 11(5):e01143. PubMed ID: 37800597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
    Snyder BD; Rowland A; Polasek TM; Miners JO; Doogue MP
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1115-22. PubMed ID: 25028073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
    Stemkens R; Jager Vd; Dawson R; Diacon AH; Narunsky K; Padayachee SD; Boeree MJ; van Beek SW; Colbers A; Coenen MJH; Svensson EM; Fuhr U; Phillips PPJ; Te Brake LHM; Aarnoutse RE;
    Antimicrob Agents Chemother; 2023 Oct; 67(10):e0068323. PubMed ID: 37768317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
    Edwards JE; Eliot L; Parkinson A; Karan S; MacConell L
    Adv Ther; 2017 Sep; 34(9):2120-2138. PubMed ID: 28808886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
    Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
    J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
    Johansson S; Read J; Oliver S; Steinberg M; Li Y; Lisbon E; Mathews D; Leese PT; Martin P
    Clin Pharmacokinet; 2014 Sep; 53(9):837-47. PubMed ID: 25117183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
    Khatri A; Cheng L; Camez A; Ignatenko S; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Jun; 58(6):805-814. PubMed ID: 30574672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers.
    Nakamura T; Shimizu H; Kawaguchi A
    Clin Ther; 2020 Nov; 42(11):2171-2183.e4. PubMed ID: 33153727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
    Xiao JJ; Nowak D; Ramlau R; Tomaszewska-Kiecana M; Wysocki PJ; Isaacson J; Beltman J; Nash E; Kaczanowski R; Arold G; Watkins S
    Clin Transl Sci; 2019 Jan; 12(1):58-65. PubMed ID: 30427584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.